Compare CFFN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | CTMX |
|---|---|---|
| Founded | 1893 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 977.1M |
| IPO Year | 2010 | 2015 |
| Metric | CFFN | CTMX |
|---|---|---|
| Price | $7.79 | $3.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $7.25 | ★ $12.10 |
| AVG Volume (30 Days) | 672.5K | ★ 2.9M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | $16,300,000.00 | ★ $76,201,000.00 |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $6.62 | $7.61 |
| P/E Ratio | $24.28 | ★ $22.58 |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $5.71 | $1.72 |
| 52 Week High | $7.97 | $8.21 |
| Indicator | CFFN | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 36.09 |
| Support Level | $7.47 | $3.40 |
| Resistance Level | $7.82 | $3.91 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 67.03 | 21.58 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.